Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics has lodged a transaction-specific prospectus with ASIC for the issuance of up to 141,250,000 new shares, attaching options, and contingent options to Lind Global Fund II, LP. This issuance marks the conclusion of Chimeric’s obligations under the subscription agreement with Lind, potentially impacting the company’s financial structure and stakeholder interests.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd., based in Melbourne, Australia, is a leader in the cell therapy industry. The company focuses on developing innovative cell therapies to treat various medical conditions, leveraging advanced biotechnology to enhance patient outcomes.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.08M
See more insights into CHM stock on TipRanks’ Stock Analysis page.